{"id":30936,"date":"2023-05-02T12:23:21","date_gmt":"2023-05-02T12:23:21","guid":{"rendered":"http:\/\/lynettelockhart.com\/client\/zimmer-biomet-raises-annual\/"},"modified":"2023-05-02T12:23:44","modified_gmt":"2023-05-02T12:23:44","slug":"zimmer-biomet-raises-annual","status":"publish","type":"post","link":"http:\/\/lynettelockhart.com\/client\/zimmer-biomet-raises-annual\/","title":{"rendered":"Zimmer Biomet raises annual forecasts on knees and hips unit strength"},"content":{"rendered":"<p>(Reuters) &#8211;     Zimmer Biomet Holdings Inc raised its annual sales and profit forecasts on Tuesday, banking on strong demand for its knees and hips products amid a sustained recovery in surgical procedures in the United States.<\/p>\n<p>Shares of the Indiana-based medical device maker rose 3.72% to $144 before the bell, also buoyed by better-than-expected first-quarter results.<\/p>\n<p>Zimmer Biomet&#8217;s upbeat outlook comes after several medical device makers, including Stryker Corp and larger rival Abbott Laboratories, raised their forecasts as easing staffing shortages at hospitals aid a recovery in medical procedures.<\/p>\n<p>Zimmer Biomet, which offers products such as knee replacements and surgical robots, now expects a profit of $7.40 to $7.50 per share for 2023, compared with $6.95 and $7.15 per share previously forecast. Analysts on average were expecting a profit of $7.06 per share, according to Refinitiv data.<\/p>\n<p>The company expects revenue to grow 5%-6% this year, compared with its previous forecast of 1.5%-3.5%.<\/p>\n<p>&#8220;Investor focus is largely on Zimmer&#8217;s ability to take a share in the knee and head market and the adoption of the company&#8217;s new launches,&#8221; BTIG analyst Ryan Zimmerman told Reuters before the results.<\/p>\n<p>Analysts have highlighted that Zimmer&#8217;s smart implant that was authorized by the U.S. health regulator in November for cementless knee replacement procedures will have a broad market opportunity.<\/p>\n<p>The medical device maker&#8217;s revenue rose 10% to $1.83 billion in the first quarter, beating analysts&#8217; average estimates of $1.70 billion.<\/p>\n<p>Excluding items, the company made a profit of $1.89 per share for the quarter ended March 31, compared with analysts&#8217; estimates of $1.64 per share.<\/p>\n<p \/>\n<p> (Reporting by Sriparna Roy in Bengaluru; Editing by Subhranshu Sahu)<\/p>\n<p><a href=\"http:\/\/lynettelockhart.com\/client\/zimmer-biomet-raises-annual\/the-logo-of-medical-implants-maker-zimmer-biomet-is-seen\/\"><img decoding=\"async\" src=\"http:\/\/lynettelockhart.com\/client\/wp-content\/uploads\/Reuters_Direct_Media\/USOnlineReportBusinessNews\/tagreuters.com2023binary_LYNXMPEJ410GX-VIEWIMAGE.jpg\" alt=\"tagreuters.com2023binary_LYNXMPEJ410GX-VIEWIMAGE\"><\/a><\/p>\n<p><a href=\"http:\/\/lynettelockhart.com\/client\/zimmer-biomet-raises-annual\/file-photo-a-robot-grinds-a-medical-implant-at-a\/\"><img decoding=\"async\" src=\"http:\/\/lynettelockhart.com\/client\/wp-content\/uploads\/Reuters_Direct_Media\/USOnlineReportBusinessNews\/tagreuters.com2023binary_LYNXMPEJ410GT-VIEWIMAGE.jpg\" alt=\"tagreuters.com2023binary_LYNXMPEJ410GT-VIEWIMAGE\"><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Reuters) &#8211; Zimmer Biomet Holdings Inc raised its annual sales and profit forecasts on Tuesday, banking on strong demand for its knees and hips products amid a sustained recovery in surgical procedures in the United States. Shares of the Indiana-based medical device maker rose 3.72% to $144 before the bell, also buoyed by better-than-expected first-quarter [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":30937,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"spay_email":"","footnotes":""},"categories":[1213],"tags":[],"class_list":["post-30936","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-u-s-business"],"jetpack_featured_media_url":"http:\/\/lynettelockhart.com\/client\/wp-content\/uploads\/Reuters_Direct_Media\/USOnlineReportBusinessNews\/tagreuters.com2023binary_LYNXMPEJ410GX-VIEWIMAGE.jpg","_links":{"self":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts\/30936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/comments?post=30936"}],"version-history":[{"count":1,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts\/30936\/revisions"}],"predecessor-version":[{"id":30939,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts\/30936\/revisions\/30939"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/media\/30937"}],"wp:attachment":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/media?parent=30936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/categories?post=30936"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/tags?post=30936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}